Journal
IMMUNOTHERAPY
Volume 8, Issue 10, Pages 1233-1244Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2016-0048
Keywords
clinical trials; immune checkpoint inhibitors; immune tolerance; immunotherapy; osteosarcoma
Categories
Ask authors/readers for more resources
Survival outcomes for osteosarcoma have plateaued since the 1980s, and patients with relapsed or refractory disease have a particularly dismal outcome. Treatment options for these patients are limited primarily due to the paucity of effective therapeutics. Immune therapies such as tumor vaccines and traditional antigen-targeted monoclonal antibodies have had limited success in solid tumors. The recent discovery of novel immune checkpoint blockade strategies and their success in adult cancers has revitalized the use of immunotherapy strategies for the treatment of solid tumors. This paper summarizes existing data supporting the use of immune therapies in osteosarcoma and the progress of this class of drugs in osteosarcoma therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available